ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,219Medicare Part D Prescriptions Filled, Including Refills

Rank: 501 out of 4623

$373K Total Retail Price of All Prescriptions

Rank: 1222 out of 4623

617 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

2% of this provider’s 617 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 8,739 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
PRAVASTATIN SODIUM 843 683 1 11
LEVOTHYROXINE SODIUM 636 567 2 1
HYDROCHLOROTHIAZIDE 408 360 3 10
AMLODIPINE BESYLATE 403 340 4 5
METFORMIN HCL 372 308 5 6
SIMVASTATIN 312 296 6 2
OMEPRAZOLE 307 253 7 7
LISINOPRIL 240 205 8 4
ATENOLOL 238 226 9 28
LOSARTAN POTASSIUM 216 157 10 21
ATORVASTATIN CALCIUM 208 177 11 12
FUROSEMIDE 193 178 12 8
GLIMEPIRIDE 190 166 13 38
METOPROLOL SUCCINATE 186 152 14 13
METFORMIN HCL ER 179 157 15 51
ZOLPIDEM TARTRATE 175 137 16 18
QUINAPRIL HCL 158 136 17 157
BENAZEPRIL HCL 132 124 18 70
MELOXICAM 129 112 19 27
SYNTHROID 127 107 20 73
SERTRALINE HCL 125 97 21 26
LOSARTAN-HYDROCHLOROTHIAZIDE 125 113 21 46
FLUTICASONE PROPIONATE 124 102 23 32
NEXIUM 119 62 24 17
ALENDRONATE SODIUM 107 106 25 22
ESCITALOPRAM OXALATE 106 95 26 75
BENAZEPRIL-HYDROCHLOROTHIAZIDE 87 70 27 212
PROAIR HFA 81 68 28 64
FELODIPINE ER 78 78 29 174
ALLOPURINOL 78 77 29 37
CITALOPRAM HBR 78 72 29 23
VERAPAMIL ER 76 62 32 96
METOPROLOL TARTRATE 70 64 33 9
CLONIDINE HCL 67 61 34 40
FENOFIBRATE 66 53 35 54
AZITHROMYCIN 65 59 36 33
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 59 36 19
BENICAR 64 51 38 168
LOVASTATIN 63 52 39 34
CLOPIDOGREL 61 61 40 31
DIOVAN 60 60 41 39
POTASSIUM CHLORIDE 59 53 42 14
BYSTOLIC 58 46 43 115
LIPITOR 58 57 43 100
SULFAMETHOXAZOLE-TRIMETHOPRIM 58 51 43 68
RANITIDINE HCL 57 57 46 47
PANTOPRAZOLE SODIUM 57 54 46 35
KLOR-CON M20 57 55 46 102
CRESTOR 55 46 49 20
FLUOXETINE HCL 53 35 50 61
PLAVIX 53 51 50 45
GLIPIZIDE 51 37 52 49
LEXAPRO 50 39 53 220
AMITRIPTYLINE HCL 50 34 R 53 69
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.